

**ADDRESSING  
CLINICAL GAPS IN  
THYROID CANCER  
MANAGEMENT:  
NEW AGENTS, NEW TESTING  
PARADIGMS, AND METHODS TO  
FACILITATE MULTIDISCIPLINARY  
CARE AND COORDINATION**

**VIRTUAL SATELLITE SYMPOSIUM**

**TUESDAY, JUNE 15, 2021**

7:00 PM - 9:00 PM EDT

**PROGRAM CHAIR**

Marcia S. Brose, MD, PhD

*For more information, visit us at...*

**gotoper.com**



*Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.*

**STAY CONNECTED!** Follow us @GoToPER and share your thoughts by using #gotoper.

# Welcome

Dear Colleague:

On behalf of Physicians' Education Resource<sup>®</sup>, LLC (PER<sup>®</sup>), we would like to welcome you and thank you for choosing to attend **Addressing Clinical Gaps in Thyroid Cancer Management: New Agents, New Testing Paradigms, and Methods to Facilitate Multidisciplinary Care and Coordination**.

We will begin with an overview of the importance of genetic testing and its contribution to optimizing therapies for patients with thyroid cancer. The core of the program features case-based discussions on diagnostic and treatment approaches in different subtypes of thyroid cancer, allowing you to consider how you might handle particular cases, integrate new, relevant clinical data into your practice, and compare your patient care approaches with experts and peers.

In working together with PER<sup>®</sup>, we strive to make this activity, along with all PER<sup>®</sup> accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with thyroid cancer.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of thyroid cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER<sup>®</sup> virtual symposium and that you can attend another PER<sup>®</sup> accredited CE activity soon.

Regards,

**Marcia S. Brose, MD, PhD**

Professor of Otorhinolaryngology  
Head and Neck Surgery  
Hospital of the University of Pennsylvania  
Professor of Medicine  
Philadelphia, PA

**Phil Talamo, CHCP**

President  
Physicians' Education Resource<sup>®</sup>, LLC  
Cranbury, NJ  
ptalamo@gotoper.com

# Agenda

7:00 PM	Welcome, Introductions, Overview of Talk Topics	Marcia S. Brose, MD, PhD
7:10 PM	Genetic Testing and Targeted Therapy in Thyroid Cancer: How Have These Advances Impacted the Way We Treat This Cancer?	Jennifer J.D. Morrisette, PhD
7:30 PM	Optimizing Care for RAI-Refractory DTC	Marcia S. Brose, MD, PhD
7:50 PM	Strategic Decision-Making in Advanced MTC	Francis Paul Worden, MD
8:10 PM	Best Practices in Anaplastic Thyroid Cancer Management	Jill Gilbert, MD
8:25 PM	Medical Crossfire: Levering Expertise on the Multidisciplinary Care Team to Improvement the Management of Advanced Thyroid Cancer	Marcia S. Brose, MD, PhD; Jill Gilbert, MD; Jennifer J.D. Morrisette, PhD; Francis Paul Worden, MD
8:45 PM	Wrap-up, Post-assessment Questions, and Q&A	Marcia S. Brose, MD, PhD

Upcoming PER® Conferences	2021
<i>5th Annual International Congress on Oncology &amp; Pathology™: Towards Harmonization of Pathology and Oncology Standards - Virtual Conference</i>	Saturday, June 26
<i>5th Annual Live Medical Crossfire®: Hematologic Malignancies - Virtual Conference</i>	Saturday, July 17
<i>20th Annual International Congress on the Future of Breast Cancer® East - Hybrid Meeting</i>	July 17-18
<i>22nd Annual International Lung Cancer Congress® - Hybrid Meeting</i>	July 29 - August 1
<i>20th Annual International Congress on the Future of Breast Cancer® West - Hybrid Meeting</i>	July 30 - August 1
<i>5th Annual School of Nursing Oncology™ - Virtual Conference</i>	August 6 - 7
<i>18th Annual Annual Meeting of the International Society of Gastrointestinal Oncology® - Hybrid Meeting</i>	October 1 - 2
<i>19th Annual School of Breast Oncology® - Hybrid Meeting</i>	October 28 - 30
<i>39th Annual CFS®: Innovative Cancer Therapy for Tomorrow - Hybrid Meeting</i>	November 3-5
<i>16th Annual New York Lung Cancers Symposium® - Hybrid Meeting</i>	Saturday, November 6
<i>6th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application</i>	Saturday, December 11
Upcoming PER® Conferences	2022
<i>18th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®</i>	Saturday, February 5
<i>26th Annual International Congress on Hematologic Malignancies®</i>	February 24-27
<i>39th Annual Miami Breast Cancer Conference®</i>	March 3-6
<i>5th Annual School of Gastrointestinal Oncology®</i>	Saturday, March 26

# Activity Overview

## Target Audience

This educational activity is directed toward endocrinologists and radiation, surgical, and medical oncologists interested in the treatment of thyroid cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with thyroid cancer are also invited to participate.

## Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Explain the impact of genetic testing in diagnosis and treatment decision-making in thyroid cancer
- Evaluate the clinical profiles of current and emerging targeted therapies for the treatment of patients with RAI-refractory DTC and advanced MTC
- Translate results from landmark trials evaluating targeted agents in thyroid cancer into personalized treatment plans with a focus on multidisciplinary care optimization
- Implement proactive strategies to identify and manage treatment-related toxicities in patients with RAI-refractory DTC and advanced MTC

## Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER<sup>®</sup> website by noon Eastern Time Wednesday, June 16, 2021. To access these materials, please visit <https://www.gotoper.com/go/june2021thyroid>

## How to Claim Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<https://education.gotoper.com/activity/june2021thyroid>

The online evaluation and request for credit will be available immediately following the program and will remain available until September 15, 2021.

## Accreditation/Designation of Credit

Physicians' Education Resource<sup>®</sup>, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource<sup>®</sup>, LLC, designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource<sup>®</sup>, LLC is approved by the California Board of Registered Nursing, Provider #16669.

## Acknowledgment of Commercial Support

This activity is supported by educational grants from Blueprint, Exelixis, and Lilly.

Thank you for attending **Addressing Clinical Gaps in Thyroid Cancer Management: New Agents, New Testing Paradigms, and Methods to Facilitate Multidisciplinary Care and Coordination**

To register for upcoming accredited CE live activity or to view our online accredited CE activities, please visit [www.gotoper.com](http://www.gotoper.com). We appreciate your attendance and look forward to seeing you at future PER<sup>®</sup> accredited CE activities.

# Disclosures and Conflict of Interest (COI) Mitigation

## Faculty, Staff, and Planners' Disclosures

The following individuals have relevant financial relationships with ineligible companies to disclose\*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Stock/shareholder	Other
Marcia S. Brose, MD, PhD	Bayer Healthcare, Eisai, Loxo Oncology, Blueprint Medicines, Novartis Pharmaceuticals, Exelixis	Bayer HealthCare, Exelixis, Eisai, Loxo Oncology			Honoraria: Bayer Healthcare, Eisai
Jill Gilbert, MD	Exelixis	Exelixis, Bayer			
Jennifer JD Morrissette, PhD		Novartis Pharmaceuticals, Bayer Healthcare	National Comprehensive Cancer Network	Thermo Fisher Scientific	
Francis Paul Worden, MD	Merck, BMS, Bayer, CUE, Lilly	Merck, BMS, Eisai, Exelixis			

*\*Information accurate at time of posting*

PER<sup>®</sup> has identified and mitigated all COI prior to the start of this activity by using a multistep process.

## Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER<sup>®</sup> or any of the companies that provided commercial support for this activity.

# Faculty

## Program Chair




**Marcia S. Brose, MD, PhD**

Professor of Medicine and Otorhinolaryngology  
Head and Neck Surgery  
Hospital of the University of Pennsylvania  
Philadelphia, PA

Marcia S. Brose, MD, PhD, is a professor at the University of Pennsylvania School of Medicine, in the departments of Otorhinolaryngology, Head and Neck Surgery, and Medicine, Division of Hematology/Oncology. She is the director of the Center for Rare Cancers and Personalized Therapy at the Abramson Cancer Center and the director of the Thyroid Cancer Therapeutics Program. She received her medical degree from Cornell University Medical College, and her doctoral degree in genetics from Rockefeller University in New York, New York. Brose's research interests include the identification of novel treatments for advanced thyroid cancer, and the identification of novel treatment options for patients with rare cancers and those with specific molecular characteristics using cancer genetics and basket trials. She is the principal investigator of many active phase I to III clinical trials and is an internationally recognized leader of the field of thyroid cancer oncology.

## Faculty



**Jill Gilbert, MD**

Professor of Medicine (Hematology/Oncology)  
Director, Hematology/Oncology Fellowship Program  
Vanderbilt University Medical Center  
Nashville, TN

Dr. Gilbert is a medical oncologist who specializes in head and neck cancer as well as thyroid cancer. She will primarily be involved in developing clinical trials of novel therapeutic agents for therapy of head and neck and thyroid cancers. Additionally, she is interested in the host immune response in the head and neck cancer survivor and in patients with advanced disease who receive molecularly targeted agents.

As Director of the Hematology/Oncology Fellowship Program, she is extensively involved in training physicians to become specialists in hematology and oncology. In this role, Dr. Gilbert develops and oversees a training program that includes all aspects of clinical hematology/oncology and laboratory-based research opportunities.


# Faculty



**Jennifer JD Morrissette, PhD**

Associate Professor of Clinical Pathology and Laboratory Medicine  
Clinical Director, Center for Personalized Diagnostics  
University of Pennsylvania Perelman School of Medicine  
Philadelphia, PA

Jennifer JD Morrissette, PhD, is the laboratory director of the CytoGenomics Laboratory in the Division of Precision and Computational Diagnostics in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania. She is an associate professor of clinical pathology and laboratory medicine, where she serves as scientific director of the Clinical Cancer Cytogenetics Laboratory and the clinical director of the Center for Personalized Diagnostics (CPD). She is board-certified in clinical cytogenetics and clinical molecular diagnostics through the American Board of Medical Genetics and Genomics, and her clinical interests focus on the development, implementation, and analysis of genomic data to detect alterations relevant for oncology patients at diagnosis and throughout the course of their disease. Morrissette also serves on the board of managers for the GOAL academic consortium, chairs a working group for the International Federation of Clinical Chemistry on the Guidance for the Implementation of Custom-Made Genomic Panels, and is a member of the cytogenetics subcommittee for the Eastern Cooperative Oncology Group.



**Francis Paul Worden, MD**

Clinical investigator  
Multidisciplinary Head and Neck Oncology  
Multidisciplinary Lung Cancer  
University of Michigan Rogel Cancer Center  
Ann Arbor, MI

Francis Paul Worden, MD, received his medical degree from the Indiana University School of Medicine in 1993. Prior to attending medical school, he worked as a registered pharmacist at a large community hospital in Indianapolis. In 1997, Worden completed a combined residency in internal medicine and pediatrics at the Detroit Medical Center and finished a medical oncology/hematology fellowship at the University of Michigan. In July 2000, Worden joined the faculty at the University of Michigan Rogel Cancer Center, where he is currently working as a clinical investigator with both the multidisciplinary head and neck oncology team and the multidisciplinary lung cancer team. Worden's research interests include organ preservation in head and neck cancer and endocrine oncology.




EMPOWERING FORWARD

# The Future of Oncology NOW

Updates from the Annual Oncology Meeting

## Upcoming CE Virtual Interactive Sessions With World-Renowned Oncology Experts


JUNE 10



7:00 PM - 9:00 PM EDT

**Exploring Current and Emerging Data Sets to Move Treatment of Higher-Risk MDS Forward: A Focus on Novel Targets and Treatment Approaches**

This activity is supported by educational grants from Gilead Sciences, Inc., Novartis Pharmaceuticals Corporation, and Takeda Oncology.



7:00 PM - 9:00 PM EDT

**Show Me the Data®! Managing Clinical Challenges in Advanced EGFR Mutation-Positive NSCLC**

This activity is supported by an educational grant from Lilly USA, LLC.

JUNE 15




7:00 PM - 9:00 PM EDT

**Addressing Clinical Gaps in Thyroid Cancer Management: New Agents, New Testing Paradigms, and Methods to Facilitate Multidisciplinary Care and Coordination**

This activity is supported by educational grants from Blueprint Medicines, Exelixis, and Lilly.


JUNE 16



7:00 PM - 9:00 PM EDT

**HER2-Positive Breast Cancer Tumor Board: Aligning Patient and Evidence to Inform Sequencing Decisions in Early and Advanced Disease Real-World Care Scenarios.**

This activity is supported by an educational grant from Puma Biotechnology, Inc.



7:00 PM - 9:00 PM EDT

**Show Me The Data®: How The Experts Make Evidence-Based Treatment Decisions in Prostate Cancer**

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme.

JUNE 17




7:00 PM - 9:00 PM EDT

**Cases and Conversations™ in Advanced Renal Cell Carcinoma:**

*Leveraging Landmark Evidence and Shared Decision-Making to Chart Personalized Care Trajectories*

This activity is supported by an educational grant from Exelixis, Inc.




7:00 PM - 8:30 PM EDT

**Head and Neck Cancers Multidisciplinary Tumor Board: Decision-Making Under Evolved Treatment Paradigms**

This activity is supported by an educational grant from Merck & Co., Inc.


JUNE 22



7:00 PM - 9:00 PM EDT **RE-BROADCAST**

**Top 10 Oncogenic Markers in Advanced NSCLC: What You Need to Know About Testing, Trials, and Novel Therapies**

This activity is supported by educational grants from Amgen, AstraZeneca, Daiichi Sankyo, Inc., Genentech, Inc., Illumina, Inc., Novartis Pharmaceuticals Corporation, and Turning Point Therapeutics, Inc.




7:00 PM - 9:00 PM EDT

**Illustrated Case Discussions:**

*Practical Approaches to Treating Relapsed/Refractory DLBCL in 2021*

This activity is supported by an educational grant from MorphoSys.

JUNE 24



7:00 PM - 9:00 PM EDT

**A Virtual Exploration of Clinical Trial Evidence on XPO Inhibition Strategies:**

*Translating Key Outcomes to the Practical Management of Relapsed/Refractory Hematologic Malignancies*

This activity is supported by an educational grant from Karyopharm Therapeutics, Inc.

Register for The Future of Oncology NOW 2021 symposia series.



Scan with smartphone to explore the series

